The Economic Corner || Which Is The First New Treatment For The Alzheimer’s Disease?

This is The Economic Corner show - where we update you on all the biggest global economic announcements.

• We finally have the first new treatment for the Alzheimer’s disease. US regulators have approved a drug developed by Biogen despite a rancorous scientific debate over whether the medicine even works. The US Food and Drug Administration on Monday approved aduca-num-ab, an intravenous infusion that will cost $56,000 for a yearly course.

• Amazon Chief - Jeff Bezos plans to become one of the first civilians in space next month. He said that he will be taking Blue Origin’s first human flight just two weeks after stepping down as Amazon’s chief executive.

• Moving on to the latest news on G7 minimum global tax deal. Japanese Finance Minister Taro Aso praised the G7 minimum global tax deal, adding that it has raised the momentum for a wider deal among the G20 major economies.

• Amid China’s growing rivalry with the U.S, Chinese lawmakers are making progress on legislation to retaliate for foreign sanctions. The official Shinwa News Agency reported late on Monday that the National People’s Congress committee filed the second draft of legislation aimed at countering sanctions imposed by foreign government.

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK